Pre-eclampsia is a hypertensive disorder characterized by proteinuria that develops along the third trimester of pregnancy. It constitutes one of the main causes of feto-maternal morbidity and mortality. New markers have been searched due to the lack of a specific biochemical test which can lead to an early diagnosis. In pre-eclampsia, an increased number of erythroblasts, from maternal and fetal origin, has been described in maternal blood. The aim of the present work was to test the ability of a non-commercial antibody, developed by our group, to detect the increase of erythroblasts in patients with pregnancy-induced hypertension and thus at risk of developing pre-eclampsia. We also aimed to compare the diagnostic efficiency of erythroblast isolation from maternal blood with that of usual biochemical tests. Erythroblasts were isolated by magnetic activated cell sorting (MACS) with 2F6.3 antibody, which specifically recognizes the CD71 receptor. An increase in alanine aminotransferase, aspartate aminotransferase or urate, as well as a decrease in serum total protein or albumin, were considered as potential markers of the disease. The number of isolated erythroblasts was significantly higher in pregnant women who developed pre-eclampsia. Erythroblast isolation from maternal blood by means of 2F6.3 antibody also showed higher diagnostic efficiency (75%) than biochemical tests.
|Translated title of the contribution||Isolation of erythroblasts in maternal blood. Utility in early diagnosis of preeclampsia|
|Number of pages||5|
|State||Published - Jul 10 2007|
- Prenatal diagnosis